I'm LongbridgeAI, I can summarize articles.BTIG analyst Julian Harrison maintained a Buy rating and $20 price target for Climb Bio (CLYM), citing the unique APRIL inhibitor profile of lead asset CLYM116. The analyst highlights its differentiation from competitors like Otsuka's VOYXACT, potential scarcity premium in the IgAN market, and favorable dosing mechanism. Additionally, Wedbush also maintained a Buy rating on July 10.
Climb Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from BTIG maintained a Buy rating on the stock and has a $20.00 price target.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Julian Harrison has given his Buy rating due to a combination of factors tied to Climb Bio’s lead asset CLYM116 and the broader APRIL inhibitor landscape in IgAN. He views CLYM116, alongside JADE101, as one of the few agents with meaningful differentiation versus Otsuka’s VOYXACT, implying a scarcity premium in a therapeutic class with an estimated U.S. market opportunity exceeding $20B.
Harrison also highlights CLYM116’s unique pH-dependent “sweeper” mechanism, which may enable both strong efficacy and a favorable dosing schedule that reduces injection burden for patients who need lifelong treatment. With VOYXACT’s robust launch, high pricing, and validated long-term renal benefit setting a commercial benchmark, he believes even a modest share of this market could justify substantial upside from current levels, supporting his unchanged $20 price target and Buy recommendation on CLYM.
In another report released on July 10, Wedbush also maintained a Buy rating on the stock with a $0.00 price target.